Sensus Healthcare (NASDAQ:SRTS) Stock Price Passes Below 50-Day Moving Average – Time to Sell?

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.97 and traded as low as $2.86. Sensus Healthcare shares last traded at $3.23, with a volume of 103,027 shares trading hands.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a report on Monday. Wall Street Zen cut shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Weiss Ratings downgraded shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday. Finally, Lake Street Capital cut their price objective on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $5.83.

Sensus Healthcare Stock Up 3.4%

The firm has a market capitalization of $54.98 million, a PE ratio of -3.55 and a beta of 1.10. The company’s 50-day simple moving average is $2.99 and its 200 day simple moving average is $3.58.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.41). The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $4.60 million. Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.

Hedge Funds Weigh In On Sensus Healthcare

Several institutional investors and hedge funds have recently bought and sold shares of SRTS. EP Wealth Advisors LLC purchased a new stake in shares of Sensus Healthcare during the 2nd quarter valued at $49,000. XTX Topco Ltd purchased a new position in Sensus Healthcare during the 4th quarter worth $77,000. Jane Street Group LLC purchased a new position in Sensus Healthcare during the 4th quarter worth $79,000. Ingalls & Snyder LLC acquired a new position in Sensus Healthcare during the 4th quarter valued at about $219,000. Finally, State Street Corp increased its position in Sensus Healthcare by 5.2% during the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock valued at $276,000 after buying an additional 3,400 shares in the last quarter. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.